« Previous
Next »
Titles
- California's insurance exchange: experts tackle the big questions1
- California's uninsured: progress toward universal coverage1
- Californians maintain health insurance coverage despite national trends1
- Center for Devices and Radiological Health appeals processes: questions and answers about 517A : guidance for industry and Food and Drug Administration staff1
- Change agent: the California Health Benefit Exchange as a catalyst of finance and delivery reform1
- Changes in health coverage by race and ethnicity since implementation of the ACA: 2013-20171
- Changes to existing medical software policies resulting from section 3060 of the 21st Century Cures Act: guidance for industry and Food and Drug Administration staff1
- Changing rules for workplace wellness programs: implications for sensitive health conditions1
- Choosing wisely: selecting outcomes for comparative effectiveness research on services for adults with disabilities1
- Citizen petitions and petitions for stay of action subject to section 505(q) of the Federal Food, Drug, and Cosmetic Act1
- Closing the "doughnut hole" has helped protect millions of Medicare beneficiaries from high drug costs1
- Community health centers and Medicaid payment reform: emerging lessons from Medicaid expansion states1
- Community health centers and the President’s HIV Initiative: issues and challenges facing health centers in high-burden states and communities1
- Community health centers continued to expand patient and service capacity in 20171
- Community health centers' experiences in a more mature ACA market1
- Community health centers: growing importance in a changing health care system1
- Comparing health insurance reform options: from "building on the ACA" to single payer1
- Competing demands: operational imperatives for the California Health Benefit Exchange1
- Compliance policy for certain compounding of oral oxitriptan (5-HTP) drug products for patients with tetrahydrobiopterin (BH4) deficiency: immediately in effect guidance for industry1
- Compounded drug products that are essentially copies of a commercially available drug product under Section 503A of the Federal Food, Drug, and Cosmetic Act1